Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
10.68
+0.40 (3.89%)
At close: Jun 18, 2025, 4:00 PM
10.95
+0.27 (2.53%)
After-hours: Jun 18, 2025, 7:25 PM EDT
Lyra Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Lyra Therapeutics stock have an average target of 16, which predicts a 49.81% increase from the current stock price of 10.68.
Price Target: $16 (+49.81%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Lyra Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $2 → $16 | Hold | Maintains | $2 → $16 | +49.81% | Jun 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $100 | Hold | Reiterates | $100 | +836.33% | Mar 14, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $100 | Hold | Reiterates | $100 | +836.33% | Aug 15, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 20, 2024 |
Financial Forecast
Revenue This Year
1.17M
from 1.53M
Decreased by -23.66%
Revenue Next Year
16.23M
from 1.17M
Increased by 1,286.17%
EPS This Year
-28.69
from -71.75
EPS Next Year
-33.83
from -28.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.6M | 42.0M | 27.3M | ||
| Avg | 1.2M | 16.2M | 26.5M | ||
| Low | 392,000 | 392,000 | 25.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.6% | 3,486.7% | 68.2% | ||
| Avg | -23.7% | 1,286.2% | 63.4% | ||
| Low | -74.4% | -66.5% | 57.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -18.90 | -16.28 | -35.70 |
| Avg | -28.69 | -33.83 | -34.68 |
| Low | -40.67 | -42.14 | -33.32 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.